Misoprostol + Oxytocin

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postpartum Hemorrhage

Conditions

Postpartum Hemorrhage

Trial Timeline

Mar 1, 2007 → Jan 1, 2008

About Misoprostol + Oxytocin

Misoprostol + Oxytocin is a phase 3 stage product being developed by Cipla for Postpartum Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT01373359. Target conditions include Postpartum Hemorrhage.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT01373359Phase 3Completed

Competing Products

20 competing products in Postpartum Hemorrhage

See all competitors
ProductCompanyStageHype Score
QuetiapineAstraZenecaPhase 2
52
Azithromycin + Azithromycin and amoxicillin + PlaceboMerckApproved
85
Eptacog alfa (NovoSeven)Novo NordiskApproved
84
Eptacog alfa (activated)Novo NordiskPre-clinical
22
aripiprazoleBristol Myers SquibbPhase 3
76
fibrinogen concentrate + PlaceboCSLPhase 1/2
40
SAGE-217 15/20 mg Oral Solution + Placebo + SAGE 217 30 mg CapsulesBiogenPhase 3
74
SAGE-217 + PlaceboBiogenPhase 3
74
ZuranoloneBiogenPre-clinical
20
ZuranoloneBiogenPre-clinical
20
LPCN 1154A + PlaceboLipocinePhase 3
69
Goserelin 3.6 mg implant + PlaceboBrain BiotechPre-clinical
15
ZULRESSO (brexanolone) injectionSupernus PharmaceuticalsPre-clinical
18
Placebo + SAGE-547 90 μg/kg/hSupernus PharmaceuticalsPhase 3
72
ZULRESSO®Supernus PharmaceuticalsApproved
80
SAGE-547Supernus PharmaceuticalsPhase 2
47
Placebo + SAGE-547 60 μg/kg/h + SAGE-547 90 μg/kg/hSupernus PharmaceuticalsPhase 3
72
SAGE-547 + PlaceboSupernus PharmaceuticalsPhase 2
47
GH001GH ResearchPhase 2
47
BrexanoloneBrain BiotechPre-clinical
15